Subscribe to Email Alerts
Menu
About Us
About INOVIQ
Market Opportunity
Board
Management
Medical & Scientific Advisory Board
Partners
Distributors
Compliance
Careers
Technology
Our Science
NETs Platform
SubB2M Platform
BARD1 Biomarker Technology
hTERT ICC Assay
Intellectual Property
Publications
Resources
Business Development
Products
Our Products
EXO-NET® Pan-Exosome
Product Overview
Technical Information
Data & Figures
Ordering
hTERT ICC Test
Pipeline
Development Pipeline
NeuCA15-3 Test
NeuCA125 Test
EXO-Ovarian Cancer Test
Exosome Therapeutics
Investors
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
News & Events
INOVIQ in the News
Conferences & Events
Contact
Contact Us
Subscribe to Email Alerts
Analyst Reports
Heading &
Sub-heading can be edited through HQI
Investors
>
Analyst Reports
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
Analyst Reports
Filter by Year:
2024
2023
2022
14-Dec-2022
OC97 study confirms EXO-NET utility for EV biomarker discovery
29-Nov-2022
EXO-NET kicks off in US; exosome work centralised in Melbourne
7-Nov-2022
MST Access: 1 1QFY23 closes with healthy cash balance
19-Oct-2022
MST Access: IIQ agrees to develop SubB2M test targeting pan-cancer diagnostic
25-Aug-2022
MST Access: Next-Gen Precision Diagnostics
1
